<DOC>
	<DOCNO>NCT00781690</DOCNO>
	<brief_summary>The current clinical study aim define index Anti Xa , marker evaluate activity heparin , end dialysis treatment show possibility decrease heparin dose hemodialysis use Evodial hemodialyzer . Actually , elevate value AntiXa end dialysis treatment increase risk bleed patient diabetic retinopathy , instance case fall home .</brief_summary>
	<brief_title>Reduction Heparin Dose Dialysis With Evodial System</brief_title>
	<detailed_description>In parallel new hemodialyzer , Evodia blood line develop improve characteristic extracorporeal circuit term reduce activation coagulation system lower deposit clot component . The aim provide system ( hemodialyzer extracorporeal circuit ) low thrombogenicity use low heparin dose order reduce patient ' bleed risk end HD treatment . Measurements TAT ( Thrombin-Antithrombin ) , marker activation coagulation , perform study order evaluate thrombogenicity system . The ionic clearance collect treatment evaluate performance hemodialyzer . The study divide three step - Period 1 : Usual heparin dose usual hemodialyzer standard blood line ( baseline ) , - Period 2 : Decrease heparin dose Evodial hemodialyzer standard bloodline - Period 3 : Lowest heparin dose define step 2 use system Evodial hemodialyzer SMA bloodline . Each patient include study perform three step . As risk extracorporeal circuit clot rather important , control group ( usual hemodialyzer heparin decrease dose ) perform .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion criterion Patients suffer chronic renal failure , Patients treat HD three time week least 3 month , stable heparin dose filter , Patients treat 44.5 hour HD mode blood flow 300350 ml/min , Patients either LMWH ( Enoxaparin , Nadroparin , Tinzaparin ) UFH use , Patients wellfunctioning vascular access judge investigator , Patients treat either AK , Innova Integra dialysis machine equip ionic dialysance device , Patients old 18 year , Patients negative serology ( AIDS , Hepatitis ) Patients sign consent participate study . Exclusion criteria Patient HIT know heparin allergy , Patient treat HD single needle mode , Patients catheter , Patients acute inflammatory event may affect , judge investigator patient ' safety study result , Patients participate study could interfere objective study , Patients active malignant disease , Patients receive heparin outside dialysis treatment , Patients guardianship , Pregnant woman , nurse mother woman plan pregnancy course study , Patients serious history coagulopathy , Patients receive AntiVitamin K medication , Patients receive association anti platelet agent , Patients heparin dose reduced technical reason ( exclude patient receive low heparin dose possibility reduction ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Chronic kidney failure</keyword>
	<keyword>Heparin</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Biocompatibility</keyword>
</DOC>